


PHARMACEUTICAL 2023



Phio Pharmaceuticals Corp. Rank 216 of 446





PHARMACEUTICAL 2023



Phio Pharmaceuticals Corp. Rank 216 of 446

The relative strengths and weaknesses of Phio Pharmaceuticals Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phio Pharmaceuticals Corp. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Phio Pharmaceuticals Corp. is the variable Net Income, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 97%, being 54% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	12,446
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,939
Liabilities, Non-Current	35
Other Assets	185
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-18
Other Revenues	0
Property and Equipment	183
Research and Development	7,012
Selling, General and Administrative Expense	4,450

Output Variable	Value in 1000 USD
Assets	12,814
Liabilities	1,974
Expenses	11,462
Revenues	0
Stockholders Equity	10,840
Net Income	-11,480
Comprehensive Net Income	-11,480
Economic Capital Ratio	97%

